Trouillas P, Xie J, Getenet J C, Adeleine P, Nighoghossian N, Honnorat J, Riche G, Derex L
Centre de Recherches sur l'Ataxie et Unité Cérébrovasculaire, Hôpital Neurologique, Lyon.
Rev Neurol (Paris). 1995 Dec;151(12):708-13.
We propose a serotonergic hypothesis for cerebellar ataxia. The levorotatory form of 5 hydroxytryptophan has been shown to be partially active in subtypes of cerebellar ataxia, including cerebellar cortical atrophy (CCA). Buspirone, a 5-HT1A agonist usable in human medicine, has been studied in a group of 14 patients with cerebellar cortical atrophy. Patients were given Buspirone for 2 months. The evaluation of cerebellar ataxia was made by a semi-quantitative scale, 10 fully quantitative measures and measurements of the sway path and sway area of the center of gravity at posturography. The primary endpoints were the modifications of the ataxia scores. At 2 months, the decrease of the ataxia scores was significant, both in the intention-to-treat (14 cases) and target (11 cases) populations. In the target population, secondary endpoints like the time measurements for pronouncing a standard sentence, the time for drawing a ladder and posturographic parameters were significantly improved; the mean global ataxia score was improved by 37.4%. These preliminary data might confirm a link between cerebellar ataxia and the metabolism of serotonin.
我们提出了一种关于小脑共济失调的血清素能假说。左旋5-羟色氨酸已被证明在包括小脑皮质萎缩（CCA）在内的小脑共济失调亚型中具有部分活性。丁螺环酮是一种可用于人类医学的5-HT1A激动剂，已在一组14例小脑皮质萎缩患者中进行了研究。患者服用丁螺环酮2个月。通过半定量量表、10项完全定量测量以及姿势描记法对重心摆动路径和摆动面积的测量来评估小脑共济失调。主要终点是共济失调评分的变化。2个月时，在意向性治疗人群（14例）和目标人群（11例）中，共济失调评分的降低均具有显著性。在目标人群中，诸如朗读标准句子的时间测量、画梯子的时间以及姿势描记参数等次要终点均有显著改善；平均总体共济失调评分提高了37.4%。这些初步数据可能证实了小脑共济失调与血清素代谢之间的联系。
